CNTB Stock Analysis: Buy, Sell, or Hold?
CNTB - Connect Biopharma Holdings Limited Ordinary Shares
$0.93
-0.05 (-5.38%)
▼
5d:
-14.17%
30d:
-66.41%
90d:
-60.72%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When CNTB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CNTB is down 14.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CNTB is down 14.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CNTB is currently trading at $0.93, which is considered oversold relative to its 30-day fair value range of $1.11 to $2.22.
Technical Outlook: Technically, CNTB is in a downtrend. Immediate support is located at $0.89, while resistance sits at $1.89. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $5.88 (+533.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CNTB is in a downtrend. Immediate support is located at $0.89, while resistance sits at $1.89. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $5.88 (+533.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.11 -
$2.22
Company Quality Score
53/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
72.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (50/100)
- BEARISH: Downward momentum (-5.4%)
- BULLISH: Trading 533.8% below Wall St target ($5.88)
- WARNING: Composite score 53/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.11 -
$2.22
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.89
Resistance Level
$1.89
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.29
Wall Street Target
$5.88
(+533.8%)
Revenue Growth (YoY)
5666.7%
Share & Embed Analysis
Last updated: October 03, 2026 1:38 PM ET
Data refreshes hourly during market hours. Next update: 2:38 PM
Data refreshes hourly during market hours. Next update: 2:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CNTB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 71 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$75 | 60 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$28 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 58 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$95 | 57 HOLD |
